RYONCIL success turns Mesoblast into a real business
- RYONCIL is FDA-approved for pediatric steroid-refractory acute graft-versus-host disease.
- The launch generated $115M in FY26 net sales, hitting full-year guidance.
- More than 50 treatment centers are onboarded, with coverage for 98 percent of US lives.
- The upside relies on adult GVHD, REVASCOR for LVAD heart patients, and chronic low back pain.
- The main test is whether hospitals continue accepting very high treatment costs as use expands.
A real launch confirms the model
Mesoblast has crossed the line from a research story to a commercial biotech. RYONCIL, its first approved product, produced $115M of net sales in fiscal 2026. The company successfully established a commercial footprint, onboarding more than 50 transplant centers and securing broad insurance coverage.
The bull case is simple. A small launch team reached the transplant centers that matter. Payers have covered the drug without strict rules that force patients to try another drug first. With a newly cleared Phase 3 trial for pediatric Duchenne muscular dystrophy, the pipeline holds significant optionality.
The bear case centers on price and proof. RYONCIL has a high wholesale price of $194,000 per infusion. That price must hold as more hospitals use it and insurers see more claims. Mesoblast also still has costly trials to run.
The next major catalysts are pipeline readouts. The company plans a full filing for REVASCOR in LVAD patients. It also expects data from its 350-patient chronic low back pain Phase 3 study in the second half of 2027.
Tiny market first, partners later
Mesoblast sells allogeneic cell therapy. Allogeneic means the cells come from donors, not from each patient. That matters because donor-derived cells can be made in batches and shipped to hospitals, looking more like a standard drug than a custom procedure.
For pediatric GVHD, the company uses a narrow sales model. It relies on a small internal team of key account managers targeting major US transplant centers. This fits an orphan disease where a few expert hospitals treat most patients.
For larger markets, Mesoblast is not trying to build a massive salesforce. In areas like chronic low back pain and adult heart failure, it expects to use regional partners, including its existing EU partnership with Grunenthal, so outside companies handle distribution.
The protective moat is intellectual property and manufacturing know-how. Mesoblast says it has more than 1,000 patents granted or filed, with key protection lasting into 2037 to 2043. The weak point is that patents do not remove clinical, regulatory, or payer risk.
One approved drug, multiple shots
RYONCIL for pediatric GVHD
RYONCIL is approved in the US for children with severe steroid-refractory acute GVHD. This is the product driving current revenue.
Adult GVHD expansion
Mesoblast plans a pivotal study using RYONCIL with Jakafi in adult GVHD. Management says this could address a population roughly three times the pediatric size.
Pediatric Duchenne
The FDA recently cleared an application to begin a Phase 3 trial for RYONCIL in pediatric Duchenne muscular dystrophy.
REVASCOR for LVAD heart patients
REVASCOR targets ischemic chronic heart failure patients with inflammation who have a left ventricular assist device. The company is preparing a full regulatory filing.
Rexlemestrocel for chronic low back pain
The STRO3+ cell line completed treating 350 patients in a confirmatory Phase 3 trial for chronic low back pain. Data is expected in the second half of 2027.
RYONCIL dominates the revenue mix
With $115M in FY26 net sales from RYONCIL, product sales now overwhelmingly dominate the revenue mix compared to historical royalty streams.
What could still break
RYONCIL price pressure
High impact · Medium oddsThe early launch is strong, but the price is high. RYONCIL costs $194,000 per infusion. If hospitals or insurers push back as volume grows, future revenue could fall short of expectations.
Hospital adoption stalls
High impact · Medium oddsMesoblast has onboarded over 50 treatment centers. The next group of centers may be harder to win. A stall would cap patient reach even if insurance coverage remains favorable.
REVASCOR filing risk
High impact · Medium oddsThe REVASCOR path relies on a planned full filing for LVAD patients. This requires a complete and convincing data package. A delay or FDA refusal would remove a major near-term catalyst.
Trial cash burn
Medium impact · Medium oddsMesoblast still needs to fund adult GVHD, chronic low back pain, and Duchenne trials. Near-term liquidity is supported by $103M in cash at June 2026 and a $125M credit facility, but trials burn cash quickly.
Pipeline readout failure
High impact · Medium oddsMuch of the stock story depends on uses beyond pediatric GVHD. Failed or unclear data in chronic low back pain or heart failure would leave Mesoblast dependent on one small orphan launch.
In one breath
What does Mesoblast sell today?
Mesoblast sells RYONCIL in the United States for pediatric steroid-refractory acute GVHD. That is a severe immune attack that can happen after a stem cell transplant.
Why is Mesoblast generating more revenue now?
The company proved that RYONCIL can sell, not just win approval. It reported $115M of net sales in fiscal 2026, marking a highly successful first full commercial year.
What is the biggest upside case?
The biggest upside comes from expanding beyond pediatric GVHD. Adult GVHD, Duchenne muscular dystrophy, REVASCOR in heart patients, and chronic low back pain represent much larger market opportunities.
What is the main risk for MESO stock?
The main risk is that early launch success stalls. Investors should watch whether hospitals keep ordering RYONCIL, insurers keep paying high prices, and the clinical pipeline moves forward without delays.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- September 6, 2026
- Score data
- September 6, 2026
- Reviewed by
- Shivam Bharuka
Comparable Biotechnology companies
Companies near Mesoblast Limited in Finn's Biotechnology industry ranking.
